Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

Dosage Schedule Schedule 1 month BP recording add diuretics, diuretics ββ-blockers blockers etc etc. titrate Candesartan Candesartan 4 ~8 mg/day Amlodipine 2.5 ~ 5 mg/day titrate Amlodipine add diuretics, , β-blockers β etc. Informed consent BP recording Enrollment 3 years or more Candesartan cilexeti : 4 to 8 mg/day. If necessary, the dose was increased up to 12 mg/day. Amlodipine Amlodipine besilate besilate : 2.5 to 5 mg/day. If necessary, the dose was increased up to 10 mg/day. If the response was insufficient, diuretics or β-blockers etc were added to the regimen in both groups.
Therapeutic Targets Targets of of Blood Pressure Age of patient (years) BP (mmHg)
Page 1 and 2: Comparison of Candesartan vs Amlodi
Page 3 and 4: 30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6: LIFE Incidence of Diabetes Mellitus
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55: Medications at at Randomization Ran
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 58 and 59: Candesartan vs vs Standard Standard
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 62 and 63: Summary IIn comparison i with i h s
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70:
Predictors of new-onset atrial fibr
show all

Comparison of Candesartan vs Amlodipine Comparison of ...

Create successful ePaper yourself

Delete template?

Save as template?